Literature DB >> 20300980

Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer.

Katsuhiro Masago1, Shiro Fujita, Tadashi Mio, Yosuke Togashi, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Kaoru Irisa, Yuichi Sakamori, Michiaki Mishima.   

Abstract

The aims of this study are to: (a) confirm the prognostic significance of the procoagulant molecules D dimer, thrombin-antithrombin complex (TAT), and plasmin-α2-plasmin inhibitor complex (PIC); (b) to evaluate hemostatic activation in patients with advanced non-small cell lung cancer (NSCLC); and (c) to delineate the relationships between markers of hemostasis and other clinical characteristics. In this study, a low PIC/TAT ratio and poor PS were significant independent negative prognostic factors for survival in patients with advanced NSCLC. The PIC/TAT ratio may become a surrogate marker for treatment with anticoagulants in the future.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20300980     DOI： 10.1007/s12032-010-9454-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  25 in total

1.  Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay.

Authors:  H Pelzer; A Schwarz; N Heimburger
Journal:  Thromb Haemost       Date:  1988-02-25       Impact factor: 5.249

2.  Prognostic impact of an activation of coagulation in lung cancer.

Authors:  J Watine
Journal:  Ann Oncol       Date:  1998-11       Impact factor: 32.976

3.  High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer.

Authors:  O Taguchi; E C Gabazza; M Yoshida; T Yamakami; H Kobayashi; T Shima
Journal:  Clin Chim Acta       Date:  1996-01-15       Impact factor: 3.786

Review 4.  The complex effects of heparins on cancer progression and metastasis in experimental studies.

Authors:  S M Smorenburg; C J Van Noorden
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

5.  Haemostatic abnormalities in lung cancer: prognostic implications.

Authors:  G Buccheri; D Ferrigno; C Ginardi; C Zuliani
Journal:  Eur J Cancer       Date:  1997-01       Impact factor: 9.162

6.  Prognostic significance of hemostatic parameters in patients with lung cancer.

Authors:  Ebru Unsal; Figen Atalay; Sükran Atikcan; Aydin Yilmaz
Journal:  Respir Med       Date:  2004-02       Impact factor: 3.415

7.  Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.

Authors:  Florian Langer; Brigitte Spath; Katja Haubold; Katharina Holstein; Guy Marx; Jan Wierecky; Tim H Brümmendorf; Judith Dierlamm; Carsten Bokemeyer; Barbara Eifrig
Journal:  Ann Hematol       Date:  2008-02-22       Impact factor: 3.673

Review 8.  From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.

Authors:  M N Levine; A Y Lee; A K Kakkar
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

9.  High plasma D-dimer level is associated with decreased survival in patients with lung cancer.

Authors:  G Altiay; A Ciftci; M Demir; Z Kocak; N Sut; E Tabakoglu; O N Hatipoglu; T Caglar
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-05-21       Impact factor: 4.126

10.  Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization.

Authors:  M C Alessi; N Chomiki; R Berthier; A Schweitzer; C Fossat; I Juhan-Vague
Journal:  Thromb Haemost       Date:  1994-12       Impact factor: 5.249
View more
  7 in total

1.  Enhanced procoagulant activity of platelets after chemotherapy in non-small cell lung cancer.

Authors:  Ruishuang Ma; Yayan Bi; Junjie Kou; Jin Zhou; Jialan Shi
Journal:  Cancer Biol Ther       Date:  2017-07-18       Impact factor: 4.742

2.  Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.

Authors:  Evren Fidan; Halil Kavgaci; Asim Orem; Mustafa Yilmaz; Bulent Yildiz; Sami Fidan; Buket Akcan; Feyyaz Ozdemir; Fazil Aydin
Journal:  Tumour Biol       Date:  2012-04-27

3.  Prognostic role of D-dimer in patients with lung cancer: a meta-analysis.

Authors:  Xuelei Ma; Yanyan Li; Jing Zhang; Jingwen Huang; Lei Liu
Journal:  Tumour Biol       Date:  2013-10-10

4.  TMEM158 May Serve as a Diagnostic Biomarker for Anaplastic Thyroid Carcinoma: An Integrated Bioinformatic Analysis.

Authors:  Han-Ning Li; Ya-Ying Du; Tao Xu; Rui Zhang; Ge Wang; Zheng-Tao Lv; Xing-Rui Li
Journal:  Curr Med Sci       Date:  2021-01-11

5.  Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.

Authors:  Xia Liu; Xiaogang Chen; Jiezuan Yang; Renyong Guo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

6.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

7.  Circulating D-Dimers Increase the Risk of Mortality and Venous Thromboembolism in Patients With Lung Cancer: A Systematic Analysis Combined With External Validation.

Authors:  Jing Li; Shanle Yan; Xiaohui Zhang; Mengqi Xiang; Chuanhua Zhang; Ling Gu; Xiaoying Wei; Chuanyun You; Shenhua Chen; Daxiong Zeng; Junhong Jiang
Journal:  Front Med (Lausanne)       Date:  2022-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.